---

---

tags : Europe    crawled date : 2021 - 06 - 11   

save search

---

Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
MRNA | News S | $107.87 3.26% 3.16% 2.4M |

Health Technology

| -51.86% | O: -2.35% H: 3.3% C: 3.28%
covid vaccine commercialization covid-19

---

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
KROS | $55.27 -0.91% -0.92% 480K |

Health Technology

| 6.19% | O: -0.61% H: 0.75% C: -1.9%
europe preclinical pre-clinical

---

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.97 6.2% 2.21% 400K |

Health Technology

| -78.94% | O: -0.18% H: 2.19% C: 0.14%
approval

---

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
TGTX | $14.25 1.06% 1.05% 3.2M |

Health Technology

| -62.87% | O: -0.24% H: 0.63% C: -0.29%
europe phase 1 therapy phase 3

---

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
AUTL | $4.5 -1.32% -1.33% 1.7M |

Health Technology

| -33.43% | O: 3.65% H: 13.94% C: 8.87%
europe cel t-cell

---

Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
FMTX | $20.01 -0.15% |

Health Technology

| -28.77% | O: -6.42% H: 0.0% C: -12.91%
europe phase 1 phase 3 phase 2

---

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M |

Health Technology

| 83.4% | O: -10.49% H: 3.1% C: -0.53%
CRSP | News M | $56.46 1.44% 1.42% 1.2M |

Health Technology

| -55.01% | O: 4.42% H: 0.63% C: -1.69%
crispr treatment europe therapy ctx001

---

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.79 2.29% 2.23% 190K |

Health Technology

| -59.3% | O: 3.49% H: 0.9% C: 0.9%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 19.19% | O: 0.49% H: 0.03% C: -0.61%
phase 2 europe als

---

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
EDIT | News | $5.465 -2.41% -2.47% 1.6M |

Health Technology

| -84.82% | O: 1.73% H: 1.89% C: -0.32%
disease treatment europe phase 1 trial phase 3 preclinical pre-clinical

---

Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival
Published: 2021-06-11 (Crawled : 08:00) - prnewswire.com
SRRA | $54.99 0.04% 0.0% |

Health Technology

| 203.73% | O: 2.26% H: 0.0% C: -0.78%
presentation europe

---

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M |

Health Technology

| -49.23% | O: 0.57% H: 0.0% C: -3.51%
phase 2 positive results europe positive results

---

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M |

Health Technology

| -49.23% | O: 0.57% H: 0.0% C: -3.51%
europe phase 3

---

New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
GBT | $68.49 0.02% -0.02% |

Health Technology

| 64.34% | O: 0.12% H: 0.0% C: -2.59%
disease europe oxbryta potential children

---

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 07:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K |

Health Technology

| -92.17% | O: -0.83% H: 7.56% C: -2.02%
europe phase 1 trial phase 3 car-t

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---